Part 2: Treatment Recently, the U.S. Food and Drug Administration approved Ocrevus {ocrelizumabl to treat adult patients with MS. This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given by a health care professional. In clinical studies, it has been shown to reduce disability progression in 24% of PPMS patients. Dr. Flynn investigates its use and the outcomes in her area. In the nearest hospital network, 472 patients with PPMS are prescribed Ocrevus. 16. How many of these patients should expect to see reduced disability progression? {4 pts) 17. What is the probability at least 120 of these patients experience reduced disability progression? {4 pts] 18. Only 99 patients experienced reduced progression after 1 year. What is the probability that 99 or less of these 19. 20. patients experience reduced disability progression? {4 pts) Dr. Flynn is concerned with the low number of successes reported. Is it reasonable for her to claim that Ocrevus does not have a success rate of 24%, as reported? Explain your answer based on your answer to #18 above, using the idea of significance. {6 pts) Dr. Flynn wants to study the prevalence of other autoimmune diseases in PPMS patients who have found Ocrevus to be a successful treatment, but needs at least 200 people to qualify for funding. How many PPMS patients should she recruit so that she has a 99% chance of receiving funding (i.e. enough patients with reduced disability progression with Ocrevus]? Explain how you got your answer. {4 pts)